BRIEF published on 12/17/2025 at 11:02, 4 months 23 days ago Valerio Therapeutics Welcomes Professor Eric Vivier to its Board of Directors Board Of Directors Oncology Immunology Valerio Therapeutics Eric Vivier
BRIEF published on 12/17/2025 at 11:02, 4 months 23 days ago Valerio Therapeutics Accueille le Professeur Eric Vivier au Conseil d'Administration Conseil D'administration Oncologie Valerio Therapeutics Immunologie Eric Vivier
BRIEF published on 12/17/2025 at 11:02, 4 months 23 days ago Valerio Therapeutics nomme le professeur Eric Vivier observateur au conseil d'administration Conseil D'administration Valerio Thérapeutique Immunologie Professeur Eric Vivier Stratégie En Oncologie
BRIEF published on 12/17/2025 at 11:02, 4 months 23 days ago Valerio Therapeutics Appoints Professor Eric Vivier as Board Observer Board Of Directors Immunology Valerio Therapeutics Professor Eric Vivier Oncology Strategy
PRESS RELEASE published on 12/17/2025 at 10:57, 4 months 23 days ago Informations privilégiées / Autres communiqués Valerio Therapeutics annonce la désignation du Professeur Eric Vivier en qualité d'Observateur de son Conseil d’Administration. Le Professeur apportera son expertise en immunologie pour développer des traitements innovants en oncologie Conseil D'administration Valerio Therapeutics Immunologie Professeur Eric Vivier Observateur
PRESS RELEASE published on 12/17/2025 at 10:57, 4 months 23 days ago Inside Information / Other news releases Valerio Therapeutics appoints Prof. Eric Vivier as Observer to Board of Directors. Prof. Vivier, a renowned immunologist, will bring over 30 years of experience to drive innovative tumor treatment approaches Board Of Directors Valerio Therapeutics Professor Eric Vivier Immunologist Tumor Treatment
PRESS RELEASE published on 10/30/2025 at 09:04, 6 months 10 days ago Rapport financier semestriel 2025
BRIEF published on 10/30/2025 at 09:03, 6 months 10 days ago Bilan financier et stratégique de Valerio Therapeutics pour le 1er semestre 2025 Recentrage Stratégique Valerio Therapeutics Résultats Financiers 2025 Plateformes V-Body Recherche Partenariats
BRIEF published on 10/30/2025 at 09:03, 6 months 10 days ago Valerio Therapeutics' financial and strategic review for the first half of 2025 Strategic Refocusing Valerio Therapeutics 2025 Financial Results V-Body Platforms Seeking Partnerships
Published on 05/09/2026 at 01:30, 15 hours 1 minute ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 16 hours 31 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 20:38, 19 hours 52 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 21 hours 18 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 21 hours 28 minutes ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 21 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 21 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 21 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 21 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 21 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
